ALS Center Strategy & Liaison Lead

Otsuka Pharmaceutical Co., Ltd.; United States; Remote; USD 158,000 - 252,000; Full time

Benefits offered by this job

Comprehensive medical, dental, vision,

401(k) match and retirement benefits

Generous paid time off

Job summary

Otsuka Pharmaceutical Co., Ltd. is seeking a Strategic Account Liaison (SAL) to support the launch and growth of its Rare Neurology Franchise, starting with ALS and the FUS-ALS program.

The role centers on communicating complex clinical data and access pathways to ALS Centers of Excellence, HCPs, and stakeholders. The SAL will develop strategic account plans, engage with KOLs and IDNs, and collaborate with Market Access and Patient Support to remove barriers to therapy while driving regional

Qualifications

• Bachelor’s degree required.
• Ideal candidates have 8–10+ years in Biotech/Pharma commercial field strategic roles.
• Experience with new product launches and IDN navigation including KOL engagement.
• Rare or ultra-rare disease experience preferred.
• Proven track record in field team coordination and cross-functional collaboration.

Responsibilities

• Communicate complex clinical data to ALS Centers of Excellence, HCPs, and key stakeholders.
• Develop and execute strategic account plans based on market insights and data.
• Navigate site of care, payer processes, and reimbursement pathways to enable therapy access.
• Collaborate with cross-functional teams to advance patient care and program objectives.
• Represent the brand at conferences and scientific events to educate on rare neurology programs.

Skills

Clinical acumen

HCP & KOL engagement

Strategic account planning

Cross-functional collaboration

Market access understanding

Education

Bachelor’s Degree

Job description

Otsuka Pharmaceutical Co., Ltd. is seeking a Strategic Account Liaison (SAL) to support the launch and growth of its Rare Neurology Franchise, starting with ALS and the FUS-ALS program.

The role centers on communicating complex clinical data and access pathways to ALS Centers of Excellence, HCPs, and stakeholders. The SAL will develop strategic account plans, engage with KOLs and IDNs, and collaborate with Market Access and Patient Support to remove barriers to therapy while driving regional